{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.3","upperLimit":"12.0","value":"9.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"PFS is defined as the interval between the date of the first dose of study medication and the date of disease progression as defined by the investigator or death due to any cause. RECIST was used to evaluate the measurability of tumor lesions, to determine target and non-target lesions at Baseline, and to evaluate tumor response or disease progression after study start. Per RECIST, PD is defined as at least a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum of the LD recorded since the treatment started or the appearance of \\>=1 new lesion and/or unequivocal progression of existing non-target lesions. Participants who did not have disease progression or did not die were censored at the follow-up visit as either follow-up ended or follow-up ongoing. Participants who received non-study anti-cancer therapies before disease progression were treated as censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pazopanib 800 milligrams (mg) once daily.","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"MEDIAN","populationDescription":"ATS Population","reportingStatus":"POSTED","timeFrame":"From the first dose of study medication to the earliest date of disease progression (PD) or death due to any cause (up to 3.460 years)","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}